Welch Timothy J, LaPatra Scott
National Center for Cool and Cold Water Aquaculture, Agricultural Research Service, U.S. Department of Agriculture, 11861 Leetown Road, Kearneysville, WV 25430, USA.
Research Division, Clear Springs Foods, Inc., PO Box 712, Buhl, ID 83316, USA.
Fish Shellfish Immunol. 2016 Feb;49:420-6. doi: 10.1016/j.fsi.2015.12.037. Epub 2016 Jan 4.
Enteric redmouth disease (ERM), caused by Yersinia ruckeri, has been controlled successfully using immersion-applied bacterin vaccines for several decades. While the host response to vaccination and the mechanism of protection of this vaccine have been elucidated, the bacterial components eliciting protection have remained unclear. Here we show that highly purified serotype O1 Y. ruckeri lipopolysaccharide (LPS) is sufficient to induce a protective response to experimental challenge in rainbow trout (Oncorhynchus mykiss). Dose response experiments demonstrated that Y. ruckeri LPS at doses of 1 ng/fish and above resulted in essentially complete protection and doses as low as 0.01 ng/fish (1.38 ng/kg) resulted in significant protection, thus demonstrating the extremely high potency of this immunogen. Analysis of the Y. ruckeri genome identified a cluster of putative O-antigen biosynthetic genes specific to serotype O1 strains. This cluster primarily consisted of genes encoding proteins predicted to function in the biosynthesis of legionamic acid, a nonulosonic acid known to be part of the O-polysaccharide repeat of O1 Y. ruckeri. Mutation of the nab2 gene, a nonulosonic acid biosynthesis gene (nab gene), resulted in production of severely truncated forms of LPS. Vaccination with bacterin vaccines derived from the nab2 mutant and its wild type parent strain demonstrated that LPS is a required component of the whole-cell bacterin vaccine and suggests that LPS is the only cellular component contributing to the protective response elicited by this vaccine. We speculate that the exceptionally high potency of Y. ruckeri LPS accounts for the unusual success of this vaccine when delivered by immersion.
肠道红嘴病(ERM)由鲁氏耶尔森菌引起,几十年来一直通过浸泡式菌苗疫苗成功控制。虽然宿主对疫苗接种的反应以及这种疫苗的保护机制已经阐明,但引发保护作用的细菌成分仍不清楚。在这里,我们表明,高度纯化的O1血清型鲁氏耶尔森菌脂多糖(LPS)足以诱导虹鳟(Oncorhynchus mykiss)对实验性攻毒产生保护性反应。剂量反应实验表明,剂量为1 ng/鱼及以上的鲁氏耶尔森菌LPS可产生基本完全的保护作用,低至0.01 ng/鱼(1.38 ng/kg)的剂量也可产生显著保护作用,从而证明了这种免疫原的极高效力。对鲁氏耶尔森菌基因组的分析确定了一组特定于O1血清型菌株的假定O抗原生物合成基因簇。该基因簇主要由编码预测在军团菌酸生物合成中起作用的蛋白质的基因组成,军团菌酸是一种已知为O1鲁氏耶尔森菌O多糖重复序列一部分的非ulosonic酸。非ulosonic酸生物合成基因(nab基因)nab2的突变导致产生严重截短形式的LPS。用源自nab2突变体及其野生型亲本菌株的菌苗疫苗进行接种表明,LPS是全细胞菌苗疫苗的必需成分,并表明LPS是这种疫苗引发的保护性反应的唯一细胞成分。我们推测,鲁氏耶尔森菌LPS的异常高效力解释了这种疫苗通过浸泡给药时异常成功的原因。